Skip to main content
OpenTrials
Completed

NCT Number: NCT00988494

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Persistent Corneal Epithelial Defect

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Santen study sites

Osaka, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has corneal epithelial defect and decreased corneal sensitivity.
  • Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.

Exclusion criteria

  • Presence of disease such as active ocular infection, or abnormal lid closure.
  • History or presence of chemical burn, Stevens - Johnson Syndrome, etc.
  • History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.

Treatment and study plan

DE-105 ophthalmic solution

Drug

Topical ocular application

Placebo Ophthalmic Solution

Drug

Topical ocular application

Primary outcomes

  1. Restoration of corneal epithelial defect

    Time frame: Every week

Secondary outcomes

  1. Visual acuity,etc.

    Time frame: Exit visit,etc.

Sponsors and collaborators

Lead sponsor

Santen Pharmaceutical Co., Ltd.

Industry

Registry information

Important dates

Study start
2009
First posted
Oct 2, 2009
Registry last updated
Nov 22, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.